Knight Therapeutics Inc.
KHTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.1% | 11.8% | 20.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 47% | 46.5% | 47% | 47.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 2% | -0.9% | -0.8% | -2.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | $0 | -$0 | -$0 | $0 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 1.2% | -5.1% | -10.2% | 6.4% |
| EPS | 0.045 | -0.16 | -0.26 | 0.13 |
| % Growth | 127.9% | 38.5% | -300% | – |
| EPS Diluted | 0.043 | -0.16 | -0.26 | 0.13 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 17.3% | 12.5% | 8.6% | 17.5% |